SecBot SecBot

XTLB

XTL BIOPHARMACEUTICALS LTD
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001023549 Biotech & Drug Discovery
$2.02 +0.05 (+2.54%)
Oct 23 4:00 PM ET · prev $1.97
Market cap
$4.8M
Nano cap
1 year
−57.9%
from $4.80 · Oct 27
30 days
−9.4%
from $2.23
52-week range
$1.87–4.80
−58% from high · low Oct 21
Avg volume 20D
9.1K
Oct 6 spike 37.0K
Short interest
🔒 Subscribers only
Filing reports
6
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL XTL Biopharmaceuticals filed a 6-K reporting the resignation of external director Iris Shapira Yalon for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    14% below its 50-day average. New closing low $1.87 on Oct 21.

Who's buying

13F
Top holderSharesValue
RHUMBLINE ADVISERS6,228$17.0K
UBS Group AG125$341.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2015
Recent actions
DateFirmActionRating
May 8, 2015HC Wainwright & Co.
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 21, 2026
Listing
Listing Status: XTLB — Normal (was Deficient & Delinquent)
XTL Biopharmaceuticals Ltd. - American Depositary Shares | Nasdaq Financial Status Indicator H → N
Jun 30, 2026
M&A
XTL Completed the Acquisition of Psyga Bio Ltd.
expands its IP portfolio to clinical-stage biopharmaceutical assets
May 22, 2026
Delisting
XTL Announces Receipt of Staff Delist Determination from Nasdaq
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced…
May 1, 2026
Short interest
FTD: XTLB — 241,231 shares ($0.9M) failed to deliver
Settlement: 20260501, Price: $3.90, FTD Value: $940,800.9, XTL BIOPHARMACEUTICALS LTD SPO
Apr 30, 2026
Short interest
FTD: XTLB — 303,157 shares ($1.1M) failed to deliver
Settlement: 20260430, Price: $3.56, FTD Value: $1,079,238.92, XTL BIOPHARMACEUTICALS LTD SPO

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
XTL Biopharmaceuticals filed a 6-K reporting the resignation of external director Iris Shapira Yalon for personal…
6-K — Impact 2/10
Jul 21, 2026 Listing status
Listing Status: XTLB — Normal (was Deficient & Delinquent)
XTL Biopharmaceuticals Ltd. - American Depositary Shares | Nasdaq Financial Status Indicator H → N
Jun 30, 2026 SEC
XTL Biopharmaceuticals filed its FY2025 20-F revealing a net loss of $6.97M, cash of only $76k, and an accumulated…
20-F — Impact 7/10
Jun 29, 2026 SEC
XTL Biopharmaceuticals held its Extraordinary General Meeting on June 29, 2026, and all proposals were approved…
6-K — Impact 6/10
Apr 29, 2026 Press
XTL Biopharmaceuticals announced a definitive agreement to acquire 100% of Psyga Bio Ltd., a psychedelic therapeutics…
Impact 7/10

SecBot reports

6 filings · 1 press release · 0 bullish · 2 bearish · 3 mixed · 1 neutral
All XTLB filing & press-release reports (7)